415 related articles for article (PubMed ID: 25262806)
1. Bedaquiline: a new hope to treat multi-drug resistant tuberculosis.
Patel RV; Riyaz SD; Park SW
Curr Top Med Chem; 2014; 14(16):1866-74. PubMed ID: 25262806
[TBL] [Abstract][Full Text] [Related]
2. Bedaquiline: a novel diarylquinoline for multidrug-resistant tuberculosis.
Chahine EB; Karaoui LR; Mansour H
Ann Pharmacother; 2014 Jan; 48(1):107-15. PubMed ID: 24259600
[TBL] [Abstract][Full Text] [Related]
3. TMC207 becomes bedaquiline, a new anti-TB drug.
Palomino JC; Martin A
Future Microbiol; 2013 Sep; 8(9):1071-80. PubMed ID: 24020736
[TBL] [Abstract][Full Text] [Related]
4. Bedaquiline: a novel antitubercular agent for the treatment of multidrug-resistant tuberculosis.
Worley MV; Estrada SJ
Pharmacotherapy; 2014 Nov; 34(11):1187-97. PubMed ID: 25203970
[TBL] [Abstract][Full Text] [Related]
5. Bedaquiline: A New Hope for Shorter and Better Anti-Tuberculosis Regimens.
Riccardi N; Del Puente F; Magnè F; Taramasso L; Di Biagio A
Recent Pat Antiinfect Drug Discov; 2018; 13(1):3-11. PubMed ID: 28625141
[TBL] [Abstract][Full Text] [Related]
6. Bedaquiline as part of combination therapy in adults with pulmonary multi-drug resistant tuberculosis.
Nguyen TV; Cao TB; Akkerman OW; Tiberi S; Vu DH; Alffenaar JW
Expert Rev Clin Pharmacol; 2016 Aug; 9(8):1025-37. PubMed ID: 27322153
[TBL] [Abstract][Full Text] [Related]
7. Provisional CDC guidelines for the use and safety monitoring of bedaquiline fumarate (Sirturo) for the treatment of multidrug-resistant tuberculosis.
Centers for Disease Control and Prevention
MMWR Recomm Rep; 2013 Oct; 62(RR-09):1-12. PubMed ID: 24157696
[TBL] [Abstract][Full Text] [Related]
8. Bedaquiline.
Goulooze SC; Cohen AF; Rissmann R
Br J Clin Pharmacol; 2015 Aug; 80(2):182-4. PubMed ID: 25702772
[No Abstract] [Full Text] [Related]
9. 3,5-Dialkoxypyridine analogues of bedaquiline are potent antituberculosis agents with minimal inhibition of the hERG channel.
Sutherland HS; Tong AST; Choi PJ; Blaser A; Conole D; Franzblau SG; Lotlikar MU; Cooper CB; Upton AM; Denny WA; Palmer BD
Bioorg Med Chem; 2019 Apr; 27(7):1292-1307. PubMed ID: 30803745
[TBL] [Abstract][Full Text] [Related]
10. Current Perspective of ATP Synthase Inhibitors in the Management of the Tuberculosis.
Divita KM; Khatik GL
Curr Top Med Chem; 2021; 21(18):1623-1643. PubMed ID: 34517802
[TBL] [Abstract][Full Text] [Related]
11. New Drugs for the Treatment of Tuberculosis.
Ignatius EH; Dooley KE
Clin Chest Med; 2019 Dec; 40(4):811-827. PubMed ID: 31731986
[TBL] [Abstract][Full Text] [Related]
12. Bedaquiline: a novel antitubercular drug for multidrug-resistant tuberculosis.
Nagabushan H; Roopadevi HS
J Postgrad Med; 2014; 60(3):300-2. PubMed ID: 25121373
[TBL] [Abstract][Full Text] [Related]
13. Multidrug-resistant tuberculosis and culture conversion with bedaquiline.
Diacon AH; Pym A; Grobusch MP; de los Rios JM; Gotuzzo E; Vasilyeva I; Leimane V; Andries K; Bakare N; De Marez T; Haxaire-Theeuwes M; Lounis N; Meyvisch P; De Paepe E; van Heeswijk RP; Dannemann B;
N Engl J Med; 2014 Aug; 371(8):723-32. PubMed ID: 25140958
[TBL] [Abstract][Full Text] [Related]
14. Mutations associated with in vitro resistance to bedaquiline in Mycobacterium tuberculosis isolates in Australia.
Martinez E; Hennessy D; Jelfs P; Crighton T; Chen SC; Sintchenko V
Tuberculosis (Edinb); 2018 Jul; 111():31-34. PubMed ID: 30029911
[TBL] [Abstract][Full Text] [Related]
15. Outcomes of Bedaquiline Treatment in Patients with Multidrug-Resistant Tuberculosis.
Mbuagbaw L; Guglielmetti L; Hewison C; Bakare N; Bastard M; Caumes E; Fréchet-Jachym M; Robert J; Veziris N; Khachatryan N; Kotrikadze T; Hayrapetyan A; Avaliani Z; Schünemann HJ; Lienhardt C
Emerg Infect Dis; 2019 May; 25(5):936-943. PubMed ID: 31002070
[TBL] [Abstract][Full Text] [Related]
16. Primary Clofazimine and Bedaquiline Resistance among Isolates from Patients with Multidrug-Resistant Tuberculosis.
Xu J; Wang B; Hu M; Huo F; Guo S; Jing W; Nuermberger E; Lu Y
Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28320727
[TBL] [Abstract][Full Text] [Related]
17. Unexpected high prevalence of resistance-associated Rv0678 variants in MDR-TB patients without documented prior use of clofazimine or bedaquiline.
Villellas C; Coeck N; Meehan CJ; Lounis N; de Jong B; Rigouts L; Andries K
J Antimicrob Chemother; 2017 Mar; 72(3):684-690. PubMed ID: 28031270
[TBL] [Abstract][Full Text] [Related]
18. Bedaquiline for the treatment of resistant tuberculosis: promises and pitfalls.
Kakkar AK; Dahiya N
Tuberculosis (Edinb); 2014 Jul; 94(4):357-62. PubMed ID: 24841672
[TBL] [Abstract][Full Text] [Related]
19. Synthetic approaches towards bedaquiline and its derivatives.
Calvert MB; Furkert DP; Cooper CB; Brimble MA
Bioorg Med Chem Lett; 2020 Jun; 30(12):127172. PubMed ID: 32291133
[TBL] [Abstract][Full Text] [Related]
20. atpE Mutation in Mycobacterium tuberculosis Not Always Predictive of Bedaquiline Treatment Failure.
Le Ray LF; Aubry A; Sougakoff W; Revest M; Robert J; Bonnet I; Veziris N; Morel F
Emerg Infect Dis; 2022 May; 28(5):1062-1064. PubMed ID: 35447056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
